Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide that acts as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its novel twin-incretin pharmacology has attracted substantial research interest, as GIP and GLP-1 pathways exhibit distinct and potentially complementary effects on insulin secretion, lipid metabolism, and adipose tissue biology.

Research into tirzepatide's mechanism has illuminated how simultaneous GIP and GLP-1 receptor engagement produces additive or synergistic outcomes in energy homeostasis models. Studies have characterised its binding affinities, receptor internalisation kinetics, and downstream signalling cascades — including cAMP amplification in pancreatic beta cells and hypothalamic circuits — revealing a richer pharmacological profile than mono-agonist comparators.

As a benchmark compound for dual-incretin research, tirzepatide enables investigators to dissect the relative contributions of GIP and GLP-1 signalling and to design next-generation multi-receptor peptide therapeutics. Its unique structural features, including a balanced receptor selectivity ratio, make it indispensable in contemporary metabolic peptide science.

For research purposes only. Not for human consumption.